Kezar Life Sciences IncNASDAQ:KZR
- LAST PRICE7.4600
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close--- / 7.4600
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | KZR |
|---|---|---|
| 09:37 ET | 960 | 7.29 |
| 09:46 ET | 1600 | 7.43 |
| 09:50 ET | 300 | 7.425 |
| 09:51 ET | 100 | 7.4275 |
| 09:55 ET | 100 | 7.4275 |
| 10:00 ET | 546 | 7.4 |
| 10:09 ET | 100 | 7.39 |
| 10:13 ET | 1983 | 7.41 |
| 10:15 ET | 100 | 7.45 |
| 10:29 ET | 200 | 7.45 |
| 10:31 ET | 100 | 7.4275 |
| 10:33 ET | 100 | 7.4275 |
| 10:36 ET | 200 | 7.455 |
| 10:38 ET | 906 | 7.46 |
| 10:51 ET | 100 | 7.45 |
| 10:54 ET | 224 | 7.4 |
| 11:00 ET | 500 | 7.45 |
| 11:16 ET | 740 | 7.45 |
| 11:27 ET | 512 | 7.45 |
| 11:59 ET | 260 | 7.4425 |
| 12:12 ET | 1958 | 7.45 |
| 12:14 ET | 600 | 7.45 |
| 12:17 ET | 400 | 7.46 |
| 12:21 ET | 2300 | 7.45 |
| 12:26 ET | 100 | 7.455 |
| 01:08 ET | 542 | 7.4147 |
| 01:36 ET | 561 | 7.44 |
| 01:38 ET | 600 | 7.47 |
| 01:40 ET | 100 | 7.46 |
| 01:42 ET | 200 | 7.47 |
| 01:44 ET | 600 | 7.46 |
| 01:45 ET | 156 | 7.47 |
| 02:02 ET | 200 | 7.47 |
| 02:07 ET | 100 | 7.47 |
| 02:12 ET | 100 | 7.44 |
| 02:16 ET | 432 | 7.445 |
| 02:18 ET | 252 | 7.48 |
| 02:23 ET | 1000 | 7.445 |
| 02:27 ET | 100 | 7.505 |
| 02:30 ET | 100 | 7.49 |
| 02:38 ET | 100 | 7.44 |
| 03:35 ET | 300 | 7.4 |
| 03:46 ET | 100 | 7.44 |
| 03:48 ET | 982 | 7.48 |
| 03:50 ET | 1356 | 7.48 |
| 03:51 ET | 1395 | 7.48 |
| 03:53 ET | 1450 | 7.48 |
| 03:55 ET | 2583 | 7.48 |
| 03:57 ET | 1316 | 7.48 |
| 04:00 ET | 2946 | 7.46 |
Nov 12, 2024
*DJ Kezar Life Sciences 3Q Loss/Shr $2.78 >KZR, from 4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones
4:01PM ET on Tuesday Nov 12, 2024 by Dow JonesKezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update, from 4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones
4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones
Nov 5, 2024
Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR), from 10:58AM ET on Tuesday Nov 05, 2024 by Dow Jones
10:58AM ET on Tuesday Nov 05, 2024 by Dow Jones
Oct 28, 2024
*DJ Kezar Life Sciences Announces 1-for-10 Reverse Stock Split >KZR, from 8:30AM ET on Monday Oct 28, 2024 by Dow Jones
8:30AM ET on Monday Oct 28, 2024 by Dow JonesKezar Life Sciences Announces 1-for-10 Reverse Stock Split, from 8:30AM ET on Monday Oct 28, 2024 by Dow Jones
8:30AM ET on Monday Oct 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Kezar Life Sciences Inc | 544.3M | -0.6x | --- |
Mereo BioPharma Group PLC | 543.1M | -13.3x | --- |
SS Innovations International Inc | 512.2M | -21.5x | --- |
Altimmune Inc | 540.8M | -4.9x | --- |
Perspective Therapeutics Inc | 531.3M | -6.4x | --- |
PureTech Health PLC | 520.3M | -7.6x | --- |
Company Information
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. The Company's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). Its oncology product candidate, KZR-261, is a small molecule agent, targeting the Sec61 translocon and protein secretion pathway, being studied in an open-label Phase I clinical trial designed to evaluate safety and tolerability, pharmacokinetics and pharmacodynamics, as well to explore preliminary anti-tumor activity. This study is being conducted in two parts: dose escalation in patients with locally advanced or metastatic solid malignancies, and dose expansion in patients with selected tumor types.
Contact Information
- Headquarters
- 4000 Shoreline Ct Ste 300SOUTH SAN FRANCISCO, CA, United States 94080-2005
- Phone
- 650-822-5600
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Graham Cooper
- Director
- Christopher Kirk
- Chief Financial Officer, Secretary
- Marc Belsky
- Chief Business Officer
- Nick Mordwinkin
- Chief Legal Officer
- Mark Schiller
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $544.3M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 73.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.25 |
EPS | $-13.15 |
Book Value | $25.77 |
P/E Ratio | -0.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
